No registrations found.
ID
Source
Health condition
Glaucoom
Niet-belastende
Intracraniele druk
Distortion Product Otoacoustic Emissions
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary objective is to evaluate the use of DPOAEs as a representation of ICP in Glaucoma patients by investigating changes in DPOAE amplitudes and phase angles with changes in posture in subgroups of glaucoma patients and in healthy controls.
Secondary outcome
N/a
Background summary
The relationship between intraocular pressure (IOP) and intracranial pressure (ICP) is a crucial aspect of the pathology of Glaucoma. Alterations in either IOP or ICP that lead to a change in the pressure gradient between the two threaten the neural tissue in the eye and, if left untreated, can lead to blindness. Currently the only reliable methods of measuring ICP are by lumbar puncture or intraventricular catheter, two extremely invasive techniques. It is therefore necessary to establish an accurate non-invasive measurement of ICP for evaluating the cause and progression of Glaucoma. Current research shows that Distortion Product Otoacoustic Emissions (DPOAEs) may be able to accurately represent changes in ICP.
Study objective
The changes in DPOAEs from upright to 30 degrees HDT will be greatest for subjects who are expected to have the lowest ICP (primarily NTG subjects). Alternatively, the least amount of change in DPOAEs will occur in subjects who are expected to have the highest ICP (primarily the high IOP, non glaucomatous subjects).
ICP = Intracranial pressure; IOP = Intraocular pressure; DPOAE = Distortion product otoacoustic emissions
Study design
N/a
Intervention
N/a
Inclusion criteria
50-70 years of age
Presence of DPOAEs in one ear
For healthy controls: Upright IOP of 21mmHg or lower
For high pressure glaucoma: Diagnosed Glaucoma, upright IOP over 21mmHg before the onset of IOP lowering treatment, and established disease progression rate based on perimetry
For normal tension glaucoma: Diagnosed Glaucoma, upright IOP of 21mmHg or lower with or without IOP lowering treatment, and established disease progression rate based on perimetry
For high IOP with no glaucoma: Upright IOP of 22mmHg or higher
Written informed consent.
Exclusion criteria
No presence of DPOAEs
For healthy controls, any eye disease or family history of glaucoma
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6053 |
| NTR-old | NTR6200 |
| Other | : 201600875 |